AngioDynamics (NASDAQ:ANGO) Reaches New 12-Month High – Still a Buy?

AngioDynamics, Inc. (NASDAQ:ANGO)’s stock price reached a new 52-week high during mid-day trading on Wednesday . The company traded as high as $16.25 and last traded at $16.2160, with a volume of 12218 shares trading hands. The stock had previously closed at $15.82.

Analysts Set New Price Targets

ANGO has been the topic of a number of recent research reports. HC Wainwright increased their price objective on AngioDynamics from $16.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. Canaccord Genuity Group lifted their target price on AngioDynamics from $16.00 to $20.00 and gave the company a “buy” rating in a report on Wednesday, July 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of AngioDynamics in a research report on Friday, July 17th. Finally, Zacks Research downgraded shares of AngioDynamics from a “hold” rating to a “strong sell” rating in a report on Thursday, July 16th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, AngioDynamics presently has a consensus rating of “Hold” and a consensus target price of $19.50.

AngioDynamics Stock Up 2.3%

The stock has a 50-day simple moving average of $13.73 and a two-hundred day simple moving average of $11.95. The firm has a market cap of $668.76 million, a PE ratio of -18.59 and a beta of 0.33.

AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings results on Tuesday, July 14th. The medical instruments supplier reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.04. AngioDynamics had a negative return on equity of 5.73% and a negative net margin of 11.48%.The firm had revenue of $86.61 million during the quarter, compared to analyst estimates of $80.24 million. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. Research analysts expect that AngioDynamics, Inc. will post -0.25 earnings per share for the current year.

Insiders Place Their Bets

In other news, SVP Warren Nighan, Jr. sold 23,370 shares of the company’s stock in a transaction on Thursday, July 30th. The shares were sold at an average price of $14.72, for a total value of $344,006.40. Following the completion of the sale, the senior vice president owned 64,745 shares of the company’s stock, valued at approximately $953,046.40. This represents a 26.52% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 6.00% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in ANGO. Farther Finance Advisors LLC grew its holdings in AngioDynamics by 146.4% in the 4th quarter. Farther Finance Advisors LLC now owns 2,018 shares of the medical instruments supplier’s stock worth $26,000 after acquiring an additional 1,199 shares during the last quarter. Kemnay Advisory Services Inc. bought a new position in shares of AngioDynamics during the fourth quarter valued at about $27,000. State of Wyoming purchased a new stake in shares of AngioDynamics during the second quarter worth about $31,000. Legal & General Group Plc purchased a new stake in shares of AngioDynamics during the second quarter worth about $45,000. Finally, Russell Investments Group Ltd. grew its stake in shares of AngioDynamics by 329.5% in the third quarter. Russell Investments Group Ltd. now owns 4,188 shares of the medical instruments supplier’s stock worth $47,000 after purchasing an additional 3,213 shares during the last quarter. Institutional investors own 89.43% of the company’s stock.

About AngioDynamics

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.